Search Results
Your search for Ann H. Partridge, MD, MPH matches 45 pages
Showing 1 - 45Young Women With Breast Cancer: Discussing vs Pursuing Fertility Preservation
In 2023, nearly 300,000 new cases of invasive breast cancer were diagnosed in the United States, and approximately 56,000 new cases of ductal carcinoma in situ were diagnosed. Although most of those cancers are diagnosed in older adults, about 9% of all new cases of breast cancer are found in women ...
Can Younger Women With Hormone Receptor–Positive Breast Cancer Safely Pause Endocrine Therapy to Pursue Pregnancy?
Preserving fertility is a driving concern for many young women with breast cancer. Many of these women have hormone receptor–positive breast cancer and are treated with adjuvant endocrine therapy for 5 to 10 years, which is known to compromise fertility. Younger women who may want to take a break...
Interruption of Endocrine Therapy to Attempt Pregnancy in Women With Hormone Receptor–Positive Early Breast Cancer
In a study reported in The New England Journal of Medicine, Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, and colleagues found that temporary interruption of adjuvant endocrine therapy to attempt pregnancy was not associated with increased short-term risk of breast cancer events among ...
Interruption of Adjuvant Endocrine Therapy to Attempt Pregnancy in Women With Breast Cancer
In a study reported in The New England Journal of Medicine, Ann H. Partridge, MD, MPH, and colleagues found that temporary interruption of adjuvant endocrine therapy to attempt pregnancy was not associated with an increased short-term risk of breast cancer events among women with hormone...
Understanding Fertility Issues in Young Patients With Breast Cancer
Young women with breast cancer have many concerns about their future fertility. How confident are you in discussing their chances of a future pregnancy, the effect of breast cancer treatment and fertility interventions on these offspring, and their risk of a compromised oncologic outcome after...
‘Best of SABCS’: Top 7 Picks From the 2022 Meeting by Jame Abraham, MD, FACP
Among the high-quality abstract presentations at the San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. Each year, The ASCOPost asks our Associate Editor, breast cancer specialist Jame Abraham, MD, FACP, to give us his picks. Dr. Abraham is Chairman of ...
Can Younger Women With Hormone Receptor–Positive Breast Cancer Safely Pause Endocrine Therapy to Pursue Pregnancy?
Preserving fertility is a driving concern for many young women with breast cancer. Many of these women have hormone receptor–positive breast cancer and are treated with adjuvant endocrine therapy for 5 to 10 years, which is known to compromise fertility. Younger women who may want to take a break...
Ann H. Partridge, MD, MPH, on Interrupting Breast Cancer Treatment to Attempt Pregnancy
Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, discusses results from the POSITIVE trial, which showed that a temporary interruption of endocrine therapy in women with hormone-responsive breast cancer in order to attempt pregnancy, does not affect short-term disease outcomes. The study ...
Ann H. Partridge, MD, MPH, and Véronique Diéras, MD, on the Future of Cytotoxic Therapy: Antibody-Drug Conjugates?
Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, and Véronique Diéras, MD, of the Centre Eugène Marquis, discuss the many challenges posed by next-generation antibody-drug conjugates (ADCs). They include side effects such as hematotoxicity, gastrointestinal toxicities, and interstitial...
Ann H. Partridge, MD, MPH, and Ian E. Krop, MD, PhD, on Metastatic Breast Cancer: New Early Data on Patritumab Deruxtecan
Ann H. Partridge, MD, MPH, Dana-Farber Cancer Institute, and Ian E. Krop, MD, PhD, of Yale Cancer Center, discuss phase I/II findings on patritumab deruxtecan, a HER3-directed antibody-drug conjugate, in patients with HER3-expressing metastatic breast cancer. A pooled analysis showed antitumor...
Ann H. Partridge, MD, MPH, and Kevin Kalinsky, MD, on Breast Cancer: Latest Findings on Fulvestrant or Exemestane With or Without Ribociclib
Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, and Kevin Kalinsky, MD, of Winship Cancer Institute at Emory University, discuss phase II findings from the MAINTAIN trial, which showed a benefit in progression-free survival for patients with hormone receptor–positive/HER2-negative...
ASCO Leadership for 2022–2023 Term Announced
Individuals elected to ASCO leadership for the 2022–2023 term were announced earlier in the year. Lynn M. Schuchter, MD, FASCO, was elected to serve as the Society’s President beginning in June 2023. Dr. Schuchter will take office as President-Elect immediately after the 2022 ASCO Annual Meeting in ...
Ann H. Partridge, MD, MPH, on SABCS Meeting Highlights: Expert Perspective
Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, discusses what she considers to be the most notable presentations at the 2021 San Antonio Breast Cancer Symposium. They include the focus on early-stage disease, especially in the TEXT/SOFT, RxPonder, and KEYNOTE-522 trials, as well as...
Lynn M. Schuchter, MD, FASCO, Elected ASCO President for 2023–2024 Term
ASCO has elected Lynn M. Schuchter, MD, FASCO, a long-time member and volunteer, to serve as its President beginning in June 2023. Dr. Schuchter will take office as President-Elect immediately after the ASCO Annual Meeting in Chicago in June 2022. Seven new members were also elected to the ASCO...
Younger vs Older Women With Breast Cancer: Understanding the Differences
Younger women with breast cancer differ from their older counterparts in ways that should be appreciated by their clinicians, according to Ann H. Partridge, MD, MPH, FASCO, Vice Chair of Medical Oncology at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. At PER’s...
Ann H. Partridge, MD, MPH, on ER+, HER2– Breast Cancer: More Effective Treatments Needed
Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, discusses results from the ALTERNATE trial on response to neoadjuvant chemotherapy in postmenopausal women with clinical stage II or III estrogen receptor–positive and HER2-negative breast cancer that is resistant to endocrine therapy. The ...
Anticipate Difficulties by Patients in Adhering to Tamoxifen Therapy
Patients prescribed tamoxifen may not report when they interrupt or discontinue therapy, according to the results of a study published in the Journal of Clinical Oncology.1 Using blood draws to determine serum levels of tamoxifen among 1,177 premenopausal women with invasive breast cancer, the...
One in Six Premenopausal Women With Invasive Breast Cancer Is Nonadherent to Tamoxifen Therapy
Measuring serum levels of tamoxifen among premenopausal women being treated for invasive breast cancer identified a “worryingly high proportion of patients, one in six, who were nonadherent to therapy at only 1 year after treatment prescription,” researchers reported in the Journal of Clinical...
ASCO Honors Leaders in Cancer Care With 2019 Special Awards
ASCO and ASCO’s Conquer Cancer Foundation are proud to recognize the winners of ASCO’s Special Awards and Conquer Cancer’s Women Who Conquer Cancer Mentorship Awards and Tribute Award. The recipients of these awards have worked to transform cancer care around the world. Don’t miss the opportunity...
ASCO Honors Leaders in Cancer Care With 2019 Special Awards
ASCO and ASCO’s Conquer Cancer Foundation are proud to recognize the winners of ASCO’s Special Awards and Conquer Cancer’s Women Who Conquer Cancer Mentorship Awards and Tribute Award. The recipients of these awards have worked to transform cancer care around the world. Don’t miss the opportunity...
ASCO Honors Leaders in Cancer Care With 2019 Special Awards
ASCO and ASCO’s Conquer Cancer Foundation proudly recognize the winners of ASCO’s Special Awards, the Society's highest honors, and Conquer Cancer's Women Who Conquer Cancer Mentorship Awards. The recipients of these awards have worked to transform cancer care around the world. ASCO...
ASCO Annual Meeting Merit Awards: This Year’s Winners
The Conquer Cancer Merit Awards support oncology trainees who are first authors on abstracts selected for presentation at an ASCO scientific meeting, including the ASCO Annual Meeting and thematic symposia. Conquer Cancer recognized 127 recipients with Merit Awards at the 2018 ASCO Annual Meeting,...
Conquer Cancer 2018 Awards Presented at ASCO Annual Meeting
The Conquer Cancer Foundation of the ASCO recently announced the recipients of its 2018 ASCO Annual Meeting Merit Awards, Medical Student Rotations for Underrepresented Populations (MSR), Resident Travel Awards for Underrepresented Populations (RTA), and Long-term International Fellowship (LIFe)....
When Is Active Surveillance Appropriate in the Treatment of DCIS?
In 2017, more than 63,000 women in the United States were diagnosed with in situ breast cancer. The overwhelming majority of those women, about 83%, were diagnosed with ductal carcinoma in situ (DCIS), a condition characterized by the presence of abnormal cells confined to the breast milk ducts;...
EXPERT POINT OF VIEW: Ann H. Partridge, MD, MPH, FASCO
“The simple questions are whether ovarian function suppression adds clinical benefit in premenopausal women, and is ovarian function suppression better with an aromatase inhibitor or tamoxifen,” said formal discussant of these trials, Ann H. Partridge, MD, MPH, FASCO, Professor of Medicine at...
For Breast Cancer Specialist Ann H. Partridge, MD, MPH, Medicine Is a Family Tradition
Breast cancer specialist Ann H. Partridge, MD, MPH, was born in Manhasset, Long Island, and grew up several miles east in Muttontown, New York. Since tiny Muttontown didn’t have its own school system, Dr. Partridge went to high school in nearby Locust Valley, a town on Long Island’s North Shore,...
Expert Point of View: Ann H. Partridge MD, MPH
Ann H. Partridge MD, MPH, Director of Adult Cancer Survivorship Program at the Dana-Farber Cancer Institute, praised the “tremendous work” of Dr. Paskett and her colleagues but referred to the findings as “disappointing to say the least.”1 “Developing interventions to prevent or treat lymphedema...
Ann H. Partridge, MD, MPH, on Adolescent and Young Adult Patients: Their Survivorship Challenges
Ann H. Partridge, MD, MPH, of the Dana-Farber Cancer Institute, summarizes a session she co-chaired on the unique issues affecting adolescent and young adult patients, including their psychosocial needs and concerns that clinicians may overlook.
Praise for the ACS/ASCO Breast Cancer Survivorship Care Guideline
The recent publication of the American Cancer Society (ACS)/ASCO breast cancer survivorship care guideline is a tremendous contribution to the literature and should provide a roadmap for providers who care for patients with a history of breast cancer for years to come.1,2 The guideline, reported by ...
Increased Frequency of BRCA Mutation Testing in Young Women With Breast Cancer
Rosenberg et al found that the proportion of women diagnosed with breast cancer at age ≤ 40 years who have undergone BRCA1 and BRCA2 testing has increased during recent years. These findings, which were reported in JAMA Oncology, were part of the ongoing prospective Helping Ourselves, Helping...
Candid Discussions on Living With and After Cancer at An Evening for Cancer Survivors and Caregivers
On January 14, 2016, the Cancer Survivorship Symposium opened with An Evening for Cancer Survivors and Caregivers, an event featuring networking, a panel discussion, and an open forum to share the challenges of living with or after a cancer diagnosis. The audience included Symposium attendees as...
$13.4 Million Awarded to Study Treatment for Low-Grade Ductal Carcinoma in Situ in a Prospective, Randomized Trial
A funding award of $13.4 million hopes to answer one of the biggest questions in the current management of breast cancer: Do women with the earliest form of the disease, ductal carcinoma in situ (DCIS), need invasive surgery? Researchers at The University of Texas MD Anderson Cancer Center, Duke...
Ann H. Partridge, MD, MPH, on Patient-Reported Outcomes From the SOFT Trial
Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, on abstract S3-09, “Patient-reported endocrine symptoms, sexual functioning and quality of life in the IBCSG SOFT trial: Adjuvant treatment with tamoxifen alone vs tamoxifen plus ovarian function suppression in premenopausal women with...
Ismail Jatoi, MD, PhD, FACS, and Ann H. Partridge, MD, MPH, on the Movement Toward Bilateral Surgical Procedures
Ismail Jatoi, MD, PhD, FACS, of the University of Texas Health Science Center and Ann H. Partridge, MD, MPH, of the Dana-Farber Cancer Institute discuss the increasing movement away from breast conservation toward bilateral surgical procedures.
‘Young and Strong’ Program Addresses Multiple Needs of Women in 40s and Younger Diagnosed with Breast Cancer
“Young and Strong” is an exportable model of a program developed at Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston to address the significant challenges facing young women with breast cancer. The new model has been designed to “serve young women with breast cancer who are...
Age Not Linked to Recurrence in Observation or Trastuzumab Groups with HER2-positive Breast Cancer
Available data suggest that younger age is an independent risk factor for disease recurrence and death in women with breast cancer. However, there has not been adequate study of the interaction of age with human epidermal growth factor receptor 2 (HER2) status or anti-HER2 treatment. In an analysis ...
ASCO Honors New Group of Members With FASCO Distinction
Formerly called the ASCO Statesman Award, the Fellow of the American Society of Clinical Oncology (FASCO) distinction recognizes ASCO members for their extraordinary volunteer service, dedication, and commitment to ASCO. Their efforts benefit ASCO, the specialty of oncology, and, most importantly,...
American Society of Clinical Oncology Honors Researchers, Patient Advocates, and Leaders of the Global Oncology Community
Leaders in cancer care will be recognized as part of the American Society of Clinical Oncology Special Awards Program at the 2014 ASCO Annual Meeting. The Special Awards recognize the dedication and significant contributions of researchers, patient advocates, and leaders of the global oncology...
Clinical Trials Actively Recruiting Patients With Breast Cancer
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies for people with breast cancer. The studies include phase I and II, interventional, and observational trials evaluating new therapies; diagnostic tools; genetic counseling; the association ...
CDC Awards Grant to Program for Young Women With Breast Cancer at Dana-Farber Cancer Institute
The Centers for Disease Control and Prevention’s (CDC’s) Division of Cancer Prevention and Control has awarded a $1.75 million, 5-year grant to the Program for Young Women with Breast Cancer at Dana-Farber Cancer Institute to increase the awareness of breast cancer among women and enhance the...
Expert Point of View: Ann H. Partridge, MD, MPH
Ann H. Partridge, MD, MPH, Associate Professor of Medicine at Harvard Medical School, commented on this study to The ASCO Post: With taxanes after doxorubicin/cyclophosphamide (AC), it’s “dealer’s choice.” However, she noted that most oncologists do not give every-3-week paclitaxel now. “Many have...
‘Share the Journey’ Mobile App Aims to Understand the Different Experiences of Breast Cancer Survivors
In March 2015, Sage Bionetworks and Apple released “Share the Journey: Mind, Body, and Wellness After Breast Cancer,” a patient-centered iPhone app that tracks five common consequences of breast cancer treatment, including fatigue, cognitive function, sleep disturbances, mood changes, and a...
Majority of Women Undergoing Contralateral Prophylactic Mastectomy Have No Major Risk Factors for Developing Cancer in Both Breasts
Patients deciding to undergo contralateral prophylactic mastectomy as part of initial treatment for breast cancer is a growing challenge in the management of the disease. Removing the unaffected breast has not been shown to increase survival, and the more aggressive procedure is associated with...
Young Breast Cancer Patients With Poorer Financial Status May Experience Delays in Seeking Care
Researchers seeking to determine why breast cancers are more deadly in young women found that although only a minority of young women experience long delays between the time they detect a breast abnormality and the time they receive a diagnosis, delays in seeking care are more common in women with...
Younger Age Does Not Significantly Impact Recurrence or Benefit from Trastuzumab in Early-stage HER2-positive Breast Cancer
Available data suggest that younger age is an independent risk factor for disease recurrence and death in women with breast cancer. However, there has not been adequate study of the interaction of age with human epidermal growth factor receptor 2 (HER2) status or anti-HER2 treatment. In an analysis ...
